Clinical Trial Update: LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma [NA]

View source ↗

Summary

A clinical trial update indicates that Nanjing Legend Biotech's LCAR-F33S is being studied for relapsed/refractory multiple myeloma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LCAR-F33S

Snippet

Sponsor: Nanjing Legend Biotech Co. | Conditions: Relapsed/Refractory Multiple Myeloma(MM) | NA | Status: RECRUITING